Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Net Margin (2016 - 2025)

Collegium Pharmaceutical has reported Net Margin over the past 10 years, most recently at 8.26% for Q4 2025.

  • Quarterly results put Net Margin at 8.26% for Q4 2025, up 137.0% from a year ago — trailing twelve months through Dec 2025 was 8.05% (down 636.0% YoY), and the annual figure for FY2025 was 8.05%, down 290.0%.
  • Net Margin for Q4 2025 was 8.26% at Collegium Pharmaceutical, down from 15.05% in the prior quarter.
  • Over the last five years, Net Margin for COLL hit a ceiling of 117.26% in Q3 2024 and a floor of 359.53% in Q1 2022.
  • Median Net Margin over the past 5 years was 8.93% (2023), compared with a mean of 4.69%.
  • Biggest five-year swings in Net Margin: crashed -37871bps in 2022 and later surged 34750bps in 2023.
  • Collegium Pharmaceutical's Net Margin stood at 65.31% in 2021, then soared by 91bps to 5.55% in 2022, then skyrocketed by 484bps to 21.33% in 2023, then tumbled by -68bps to 6.89% in 2024, then grew by 20bps to 8.26% in 2025.
  • The last three reported values for Net Margin were 8.26% (Q4 2025), 15.05% (Q3 2025), and 6.37% (Q2 2025) per Business Quant data.